secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001213900-26-038061
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics FY2025 net loss $11.2M, cash $14.7M, stenoparib Fast Track
--------------------------------------------------------------------------------

- Net loss improved to $11.2M ($0.78/shr) from $25.1M ($15.65/shr) in 2024; first revenue of $320k.
- Year-end cash $14.7M; extended runway with $20M non-convertible debt financing closed March 2026.
- Stenoparib received FDA Fast Track for advanced ovarian cancer; new Phase 2 protocol implemented.
- VA-funded Phase 2 combo trial (stenoparib+temozolomide) in SCLC opened at 11 VA sites; first patients dosed early 2026.
- Jeff Ervin appointed CFO in July 2025 as part of leadership strengthening; DRP platform licensing initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026038061/0001213900-26-038061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026038061/ea0279571-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-038061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer